Skip to content
Screener

Insulet PODD Total Revenue

Total Revenue at other companies

Eli Lilly logo
Eli LillyLLY
$22.97B+47.7%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$254.56M+5.8%
Medtronic logo
MedtronicMDT
$9.81B+9.9%
Beta Bionics logo
Beta BionicsBBNX
$32.01M+37.8%
Embecta Corp. logo
Embecta Corp.EMBC
$221.8M-14.4%
Opko Health logo
Opko HealthOPK
$163.58M+4.3%

Segments

By product

See full
International$251.8M+35.5%
Drug Delivery$5.8M-43.1%

By geography

See full
U.S.$463.3M

Other financials

Income statement

See full
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions, except share and per share data)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Revenue$801.7$470.5$1,563.4$891.0
Revenue to related party178.6327.1
Total revenue801.7649.11,563.41,218.1
Cost of revenue239.1196.9471.8356.8
Gross profit562.6452.21,091.6861.3
Research and development expenses88.173.4177.8133.0
Selling, general and administrative expenses344.8257.7662.1518.4
Operating income129.7121.1251.8209.9

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's total revenue?
Insulet (PODD) reported total revenue of $801.7M in Q2 2026.
How has Insulet's total revenue changed year-over-year?
Insulet's total revenue increased by 23.5% year-over-year, from $649.1M to $801.7M.
What is the long-term trend for Insulet's total revenue?
Over 4 years (2021 to 2025), Insulet's total revenue has grown at a 25.3% compound annual growth rate (CAGR), from $1.1B to $2.71B.
What does total revenue mean?
The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Ask your AI about Insulet's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude